FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma
globalreutersAugust 21, 20241 Mins read 
Regeneron Pharmaceuticals said the FDA cited no approvability concerns for its multiple myeloma drug, linvoseltamab, other than previously identified issues with a contract manufacturer. While linvoseltamab trails bispecific antibodies currently marketed by Johnson & Johnson and Pfizer, if approved, it could bring patients an earlier treatment option.
The post FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma appeared first on MedCity News.
Recent Posts
Categories
Related Articles
Tatiana Fofanova demos Koda Health
Tatiana Fofanova is the CEO of Koda Health. She is dealing with...
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
Kura Oncology already had a broad development plan for ziftomenib in leukemias,...
Health economic value of postacute oral nutritional supplementation in older adult medical patients at risk for malnutrition
That is my recent paper with co-authors Shanshan Wang, Jason Shafrin, and...
How Much More Would People Pay in Premiums if the ACA’s Enhanced Subsidies Expired?
Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace...
Leave a comment